Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.
Deena Mary Atieh Graham, MD
Advertisement
Articles by Deena Mary Atieh Graham, MD
Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.
Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.
Deena Mary Atieh Graham, MD, discusses a pilot study evaluating RAGE inhibition to reduce therapy-related cardiotoxicity in early-stage breast cancer.
Advertisement
Latest Updated Articles
Dr Graham on the Significance of the FDA Approval of Mirvetuximab Soravtansine in Ovarian CancerPublished: May 12th 2025 | Updated:
Dr Graham on Notable Ongoing Studies in Ovarian CancerPublished: May 9th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5